X4 Pharmaceuticals (X4 Pharmaceuticals) EPS Growth Rate (Future 3Y To 5Y Estimate) : N/A (As of May. 28, 2024)

View and export this data going back to 2017. Start your Free Trial

What is X4 Pharmaceuticals EPS Growth Rate (Future 3Y To 5Y Estimate)?

EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, X4 Pharmaceuticals's EPS Growth Rate (Future 3Y To 5Y Estimate) is N/A.

Competitive Comparison of X4 Pharmaceuticals's EPS Growth Rate (Future 3Y To 5Y Estimate)

For the Biotechnology subindustry, X4 Pharmaceuticals's EPS Growth Rate (Future 3Y To 5Y Estimate), along with its competitors' market caps and EPS Growth Rate (Future 3Y To 5Y Estimate) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

X4 Pharmaceuticals's EPS Growth Rate (Future 3Y To 5Y Estimate) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, X4 Pharmaceuticals's EPS Growth Rate (Future 3Y To 5Y Estimate) distribution charts can be found below:

* The bar in red indicates where X4 Pharmaceuticals's EPS Growth Rate (Future 3Y To 5Y Estimate) falls into.

X4 Pharmaceuticals (NAS:XFOR) EPS Growth Rate (Future 3Y To 5Y Estimate) Explanation

EPS Growth Rate (Future 3Y To 5Y Estimate) s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

X4 Pharmaceuticals EPS Growth Rate (Future 3Y To 5Y Estimate) Related Terms

Thank you for viewing the detailed overview of X4 Pharmaceuticals's EPS Growth Rate (Future 3Y To 5Y Estimate) provided by GuruFocus.com. Please click on the following links to see related term pages.

X4 Pharmaceuticals (X4 Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » X4 Pharmaceuticals Inc (NAS:XFOR) » Definitions » EPS Growth Rate (Future 3Y To 5Y Estimate)

Comparable Companies

Traded in Other Exchanges

48Q:Germany

Address

61 North Beacon Street, 4th Floor, Boston, MA, USA, 02134

Website

https://www.x4pharma.com

X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream.

Executives

Paula Ragan	director, officer: President and CEO	C/O X4 PHARMACEUTICALS, INC., 955 MASSACHUSETTS AVE., 4TH FLOOR, CAMBRIDGE MA 02139
Mark Baldry	officer: Chief Commercial Officer	C/O AMICUS THERAPEUTICS, 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Arthur Taveras	officer: Chief Scientific Officer	C/O X4 PHARMACEUTICALS, INC., 61 NORTH BEACON STREET, 4TH FLOOR, BOSTON MA 02134
Mary Dibiase	officer: Chief Operating Officer	61 NORTH BEACON STREET, 4TH FLOOR, BOSTON MA 02134
Adam S. Mostafa	officer: See Remarks	C/O X4 PHARMACEUTICALS INC., 61 NORTH BEACON STREET, 4TH FLOOR, BOSTON MA 02134
Keith Woods	director	C/O X4 PHARMACEUTICALS INC., 61 NORTH BEACON STREET 4TH FLOOR, BOSTON MA 02134
Michael S Wyzga	director	RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, CAMBRIDGE MA 02139
Christophe Arbet-engels	officer: Chief Medical Officer	C/O MILLENDO THERAPEUTICS, INC., 110 MILLER AVENUE, SUITE 100, ANN ARBOR MI 48104
Murray Stewart	director	C/O NOVELION THERAPEUTICS INC., 1800-510 WEST GEORGIA STREET, VANCOUVER A1 V6B OM3
Craecker Francoise De	director	61 NORTH BEACON STREET, 4TH FLOOR, BOSTON MA 02134
Derek M Meisner	officer: General Counsel	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Diego Cadavid	officer: Chief Medical Officer	C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Alison Frances Lawton	director	39 ROBINSON ROAD, LEXINGTON MA 02420
Renato Skerlj	officer: Chief Scientific Officer	C/O X4 PHARMACEUTICALS, INC., 955 MASSACHUSETTS AVENUE, 4TH FLOOR, CAMBRIGE MA 02139
William Aliski	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949